NCT01071525

The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Rambam Health Care Campus · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

1. Treatment of Hypercholesterolemic patients with niacin will cause a significant decrease in oxidative stress and a decrease in the atherogenecity in blood samples of the patients. 2. A possible correlation between oxidative stress in hypercholesterolemic patients taking niacin to clinical hypercholesterolemia parameters is possible. 3. Using a novel biomarker will enable a precise detection of the change in the oxidative stress in hypercholesterolemic patients.

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Niacin\Laropiprant	Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant

Timeline

• Start date: 2010-04-01
• Primary completion: 2010-08-01
• Completion: 2010-10-01
• First posted: 2010-02-19
• Last updated: 2010-03-01

Locations

1 site across 1 country: Israel